Predictive Immunohistochemical Biomarkers for Antibody-Drug Conjugate Therapy in Pulmonary Cytology.
Background The management of lung cancer has undergone a major transformation with the advent of precision oncology, where treatment decisions increasingly rely on tumor specific biomarkers rather than morphology alone. A clear understanding of the interpretation and limitations of these biomarkers is essential for pathologists involved in thoracic cytopathology and precision oncology.
Background The management of lung cancer has undergone a major transformation with the advent of precision oncology, where treatment decisions increasingly rely on tumor specific biomarkers rather than morphology alone. A clear understanding of the interpretation and limitations of these biomarkers is essential for pathologists involved in thoracic cytopathology and precision oncology.
What the study was
- Study design
- Review
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Acta cytologica
Why it surfaced
Relevant Precision oncology and genomic medicine study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.